CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Cutting costs on a salary can be challenging. Learn practical ways to reduce expenses and improve your financial management skills today.
20,198 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
This year brought a sharp retreat in Accenture’s stock. The drop isn’t just a price move—it's a signal. This guide br...
Bitcoin holds near key levels as a data-heavy week unfolds. Here are three things crypto investors should watch to ga...
The Supreme Court declined to hear Alan Dershowitz's $300 million defamation suit against CNN, ending a high-profile ...
Honeywell Aerospace begins trading as an independent company with a clear capital-allocation rule: invest in the supp...
As wealth maps evolve from a pyramid to a diamond, the world learns new rules for saving, investing, and building res...
Honeywell Aerospace becomes an independent company after the June 29, 2026 spin-off, offering a focused aerospace exp...
A family-friendly theater warning highlights a common scam: fake ticket listings that imitate legitimate sites. Learn...
Two software leaders battle for your 2026 portfolio: Duolingo and Zeta Global. This guide compares business models, g...
Robinhood Chain goes live on mainnet, delivering Layer 2 scalability for tokenized assets and a suite of around-the-c...
A new, Lubin-backed nonprofit launches to accelerate institutional adoption of Ethereum and its Layer 2 ecosystem. Th...
NEXA Lending CEO Mike Kortas introduces evoLend, a new servicing platform approved to handle government-backed loans,...